Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability

Lévi, Françis; Karaboué, Abdoulaye; Gorden, Lee; Innominato, Pasquale F.; Saffroy, Raphaël; Giacchetti, Sylvie; Hauteville, D.; Guettier, Catherine; Adam, René; Bouchahda, Mohamed

doi:10.1007/s00280-010-1327-8

Cited by 46 publications

(46 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In mice, at the time of maximal DNA synthesis (mid-activity) maximal mortality is noticed and in midrest phase (DNA synthesis minimum) maximum tolerability is noticed for 5-florouracil treatment (Lévi et al 2011). Phase I, II and III clinical trials carried out in humans; Lévi et al (2011) revealed that the administration of chemotherapeutic agents at a time of day corresponding to peak tumour sensitivity can produce distinct therapeutic benefits for cancer patients. Assessment of individual rhythms (activity-rest cycle by actigraphy) is obligatory for chronotherapy to assess the individual's body clock (Lévi et al 2011).…”

Section: Chronotherapeutics Of Cancermentioning

confidence: 97%

“…A well-tailored chronopharmacological strategy can improve tumour response, overall survival and minimize side effects and toxicity in cancer patients rather than randomized clinical trials (Nakagawa et al 2006). In mice, at the time of maximal DNA synthesis (mid-activity) maximal mortality is noticed and in midrest phase (DNA synthesis minimum) maximum tolerability is noticed for 5-florouracil treatment (Lévi et al 2011). Phase I, II and III clinical trials carried out in humans; Lévi et al (2011) revealed that the administration of chemotherapeutic agents at a time of day corresponding to peak tumour sensitivity can produce distinct therapeutic benefits for cancer patients.…”

Section: Chronotherapeutics Of Cancermentioning

confidence: 98%

“…Phase I, II and III clinical trials carried out in humans; Lévi et al (2011) revealed that the administration of chemotherapeutic agents at a time of day corresponding to peak tumour sensitivity can produce distinct therapeutic benefits for cancer patients. Assessment of individual rhythms (activity-rest cycle by actigraphy) is obligatory for chronotherapy to assess the individual's body clock (Lévi et al 2011). The survival was reported to be five-fold greater in metastatic colorectal patients with healthy activity-rest rhythms than the patients with impaired activity-rest rhythms (Lévi et al 2011).…”

Section: Chronotherapeutics Of Cancermentioning

confidence: 99%

See 2 more Smart Citations

Chronotherapy: a noteworthy focal point in the treatment of cancer?

Subramanian

Jayapalan

Hashim

2014

Biological Rhythm Research

View full text Add to dashboard Cite

In mammalian systems including humans, DNA synthesis, cell cycle and mitotic index are circadian in nature. Disrupted circadian clock leads to disturbed cellular rhythms, metabolism and hormonal balance and is noticeably accountable for the uncontrolled cell division ultimately leading to cancer. About a decade ago, there are fewer evidences on the role of biological clock on tumorigenesis. Currently, a relationship between shift work and cancer, distinctively breast cancer in women and prostate cancer in men, distraction of sleep-wake cycles and augmentation of cancer development, oncostatic effects of melatonin (the internal zeitgeber of circadian system), bidirectional relationships of circadian and immune systems, the prospect of clock genes as tumour suppressors, inaccurate temporal management of oxidative stress and genotoxicity have been recounted, making the crucial role of circadian clock in carcinogenesis. This review critically evaluates present knowledge on circadian rhythms in relation to cancer and its management. The accumulating and coercing evidences could be valuable in formulating the rhythm-based therapy as a remarkable focal point in the management of cancer.

show abstract

Section: Chronotherapeutics Of Cancermentioning

confidence: 97%

Section: Chronotherapeutics Of Cancermentioning

confidence: 98%

Section: Chronotherapeutics Of Cancermentioning

confidence: 99%

See 1 more Smart Citation

Chronotherapy: a noteworthy focal point in the treatment of cancer?

Subramanian

Jayapalan

Hashim

2014

Biological Rhythm Research

View full text Add to dashboard Cite

show abstract

“…85 More recent studies have shown that biological predictors of responsiveness to specific therapeutic agents (eg, K-ras mutational status as a predictor of responsiveness to cetuximab) may be highly informative prognostic variables. [86][87][88] Prognostic Systems…”

Section: Hepatic Colorectal Adenocarcinoma Metastases Overviewmentioning

confidence: 99%

Prognostication Systems as Applied to Primary and Metastatic Hepatic Malignancies

Cho¹

2015

Surgical Oncology Clinics of North America

View full text Add to dashboard Cite

“…Sixteen patients (17.6%) had received all the five major drugs. Twenty patients received chronomodulated chemotherapy (21%) [10]. In the 84 pretreated patients, 6 complete responses (CR) and 26 partial responses (PR) were reported to the last regimen, for an overall response rate (ORR) of 38.1%.…”

Section: Patientsmentioning

confidence: 99%

Feasibility of cetuximab given with a simplified schedule every 2 weeks in advanced colorectal cancer: a multicenter, retrospective analysis

et al. 2010

View full text Add to dashboard Cite

Cetuximab was approved using a weekly schedule, alone or in combination with chemotherapy (CT). However, many CT regimens in metastatic colorectal cancer (CRC) are delivered every 2 weeks (q2wks). Preliminary data suggested that a simplified schedule using cetuximab q2wks, 500 mg/m² would be equivalent to the standard weekly administration. Medical data of all patients with advanced CRC who received cetuximab q2wks were retrospectively collected and checked for consistency by an independent monitor in 4 European centers. Ninety-one patients were treated between 2005 and 2007 when the K-RAS mutational status of tumors was not determined routinely. They received a median of 4 (0-5) previous drugs, including previous weekly cetuximab in 38.5% of patients. Cetuximab q2wks was associated with an irinotecan-based regimen in 85.7% of patients. The median number of cetuximab administrations was 6 (1-23). Skin toxicity was observed in 68.2% of evaluable patients (grade 3 in 15%). Only one grade 1 allergy was reported. In the 84 patients beyond first-line therapy, response rate was 29.3%. The median progression-free survival was 3.0 months (range 2.2-3.8), and median overall survival was 9.0 months (range 6.2-11.8). Cetuximab q2wks appears safe and effective in heavily pretreated patients and convenient in combination with q2wks CT schedules.

show abstract

Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability

Abstract: The addition of cetuximab to chronotherapy allowed safe and effective therapeutic control of metastases, including their complete resection, despite previous failure of several treatment regimens.

Cited by 46 publications

References 44 publications

Chronotherapy: a noteworthy focal point in the treatment of cancer?

Chronotherapy: a noteworthy focal point in the treatment of cancer?

Prognostication Systems as Applied to Primary and Metastatic Hepatic Malignancies

Feasibility of cetuximab given with a simplified schedule every 2 weeks in advanced colorectal cancer: a multicenter, retrospective analysis

Contact Info

Product

Resources

About